Leadoff Hitter – Spotting High-Risk Players
J.A. Randy Englert, MD, FACC
Swing for the Fences – LDL-C as the Power Hitter
Matthew Malachowski, Pharm. D., MHA
Turning the Double Play – Comprehensive Secondary Prevention
Crossing Home Plate – Building a Winning Team Culture
ASCVD Playbook | Closing the Gaps, One Inning at a Time
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Anjali Owens, MD
Ahmad Masri, MD, MS
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Roxana Mehran, MD, FSCAI
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Ellie Kelepouris, MD, FACP, FAHA
Is CKD-aP Hiding in Your Dialysis Center?
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD